Unicycive Therapeutics

Last week, our team attended the American Society of Nephrology (ASN) Kidney Week 2024, where we delivered multiple poster presentations highlighting the development progress of our two assets: Oxylanthanum Carbonate (OLC) and UNI-494. Collaborating with the medical community at #KidneyWk is always a highlight of the year for us and getting to share our positive clinical trial data around OLC, along with several other presentations made last week even more significant. Learn more about our time at ASN at https://lnkd.in/gmeKC9YD #KidneyDisease

We’ve always had a soft spot for the underdogs. Unicycive was built from a focus on finding outsized value from previously overlooked opportunities and therapies. What’s your favorite underdog story?

"Resourcefulness comes from within" 💪. Hear from our CEO, Shalabh Gupta, MD on how a commitment to being resourcesful sparked his career shift into biotech. And how that focus is integral to our company culture today. #UNCYvalues

Your kidneys work harder than you think. The best way to not have them work overtime is by fostering a healthy lifestyle–regular exercise, maintain a healthy diet, and sleep 7 - 8 hours a night. #hereforkidneydiseasepatients #kidneycare #kidneyhealth

From promising clinical trials to an NDA submission, we've had a lot to celebrate at Unicycive recently. Small. Steps. Pay. Off.

Later this month, our CEO Shalabh Gupta, MD will join many other biotech and pharma leaders to discuss some of the most important issues facing the healthcare industry at the Longwood Healthcare Leaders Boston CEO event. Shalabh will be speaking on a panel alongside other key opinion leaders about preparing for commercial deployment. We know that only together can we transform the landscape of healthcare and meaningful discussions like these continue to help us solve for unmet patient needs.

Happy Boss’s Day to our CEO, Shalabh Gupta, MD! We’re grateful for your leadership, unwavering focus on patient success, and willingness to always participate in our social content.

🌟 Employee spotlight 🌟 Atul Khare, Ph.D., M.B.A. VP, Scientific Affairs, is energized by solving challenges and is phased by absolutely zero pet peeves in the workplace.

Did you see the news yesterday, that we completed our Phase 1 trial with UNI-494? The successful study results will inform our next steps for advancement to a potential Phase 2 clinical trial in #acutekidneyinjury. https://bit.ly/4dEEl9t #AKI, #unicycive #kidneydisease

THIS resonates with us. Our team is consistently pursuing small steps forward, in and outside the office. And all of those small steps are leading to major outcomes.